WELL Health: Canaccord Increases Price Target To $8.50 Following Bought Deal

This morning Canaccord Genuity raised their 12-month price target on WELL Health Technologies (TSX: WELL) to C$8.50 from C$8.00 and reiterated their Speculative Buy recommendation on the stock following the close of their recent $80 million bought deal.

Doug Taylor, Canaccord’s analyst, now estimates that the company holds roughly $114 million in pro forma cash. Funds from the recent financing are expected to go towards “organic growth initiatives, including its recent apps.health launch, and for additional M&A and strategic investments.”

Taylor says, “Financing strengthens an already sizable war chest for accretive capital allocation.” He adds that the sizeable $114 million in cash WELL has now will go towards M&A or a list of strategic investments, such as the following.

  1. Medical and/or allied health clinics (WELL Health Clinic Network and WELL Allied)
  2. EMR platforms (WELL EMR)
  3. Digital health companies with an emphasis on patient engagement technologies (WELL Digital Health Apps)
  4. Cybersecurity (Cycura)

Although since the Circle Medical deal that was signed at the beginning of September, there has been no new deals, Taylor says, “we understand
the company currently has on the order of 10 signed letters of intent (LOI) in its M&A pipeline, noting that timing and probability of closing from the LOI stage are variable.”

Taylor then touches on their forecast for WELL’s third-quarter results, which will be announced in November. Taylor says that they expect a small growth in Digital Services revenue over the second quarter. This quarter will include early contributions from the Cycura acquisition.

Taylor expects third-quarter revenue to be $11 million and Adjusted EBITDA to be ($0.4) million. His full 2020 year revenue estimate is $44 million with EBITDA of ($0.8) million.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

This Gold Story Starts With Cash Flow | Gordon Robb – ESGold

Silverco Cusi Mine PEA: Bigger Isn’t Always Better

Fixing Heart Disease Tied to Sudden Death in Young People | David Elsley – Cardiol Therapeutics

Recommended

Cambria Drills 17.95 g/t Gold Over 22 Metres At Premier Mine

Denarius Metals Increases Bid For Emerita Resources To $0.45 Per Share

Related News

Well Health To Acquire CRH Medical For US$369.2 Million

Well Health Technologies (TSX: WELL) this morning continued with its strategy of acquiring medical-related assets,...

Monday, February 8, 2021, 07:24:11 AM

Hexo: Stifel-GMP Puts Bankruptcy On The Table For Company Following Terrible Debt Deal

On October 29th, Hexo Corp (TSX: HEXO) reported its fiscal fourth quarter financial results. The...

Monday, November 8, 2021, 03:58:00 PM

Valens Company: Analysts Downgrade Company Following Reduced Guidance

The Valens Company (TSX: VLNS) experienced a pretty wild second half of January, and analysts...

Monday, February 1, 2021, 02:39:00 PM

CloudMD Gets Price Target Cut By Canaccord Genuity

On Monday CloudMD Software & Services Inc. (TSXV: DOC) reported its fourth quarter results for...

Wednesday, May 4, 2022, 03:06:00 PM

Eight Capital Initiates Coverage On Field Trip Health With $10.20 Price Target

Earlier this week, Eight Capital launched coverage on a basket of psychedelic companies. This comes...

Friday, September 17, 2021, 10:59:00 AM